Tags

Type your tag names separated by a space and hit enter

Use of apomorphine in Parkinson's disease.
Neurol Sci. 2008 Dec; 29 Suppl 5:S383-6.NS

Abstract

In the parkinsonian patient, the striatal levels of dopamine strictly depend on peripheral levodopa levels; short half-life of levodopa is responsible for plasmatic level fluctuations, which are consistent with a pulsatile receptor stimulation of the striatal system. This sort of non-physiologic stimulation induces a change of the condition of post-synaptic neurons, which is considered responsible for the fluctuations of clinical response. In this respect, apomorphine administration, via infusion pump, may be a good therapeutic option, aimed at obtaining continuous receptor stimulation, assisting in the management of motor fluctuations in the advanced phase of the disease.

Authors+Show Affiliations

Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy. fabrizio.stocchi@sanraffaele.it

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19381769

Citation

Stocchi, Fabrizio. "Use of Apomorphine in Parkinson's Disease." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 29 Suppl 5, 2008, pp. S383-6.
Stocchi F. Use of apomorphine in Parkinson's disease. Neurol Sci. 2008;29 Suppl 5:S383-6.
Stocchi, F. (2008). Use of apomorphine in Parkinson's disease. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 29 Suppl 5, S383-6. https://doi.org/10.1007/s10072-008-1053-8
Stocchi F. Use of Apomorphine in Parkinson's Disease. Neurol Sci. 2008;29 Suppl 5:S383-6. PubMed PMID: 19381769.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of apomorphine in Parkinson's disease. A1 - Stocchi,Fabrizio, PY - 2009/4/22/entrez PY - 2009/5/16/pubmed PY - 2009/6/3/medline SP - S383 EP - 6 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol Sci VL - 29 Suppl 5 N2 - In the parkinsonian patient, the striatal levels of dopamine strictly depend on peripheral levodopa levels; short half-life of levodopa is responsible for plasmatic level fluctuations, which are consistent with a pulsatile receptor stimulation of the striatal system. This sort of non-physiologic stimulation induces a change of the condition of post-synaptic neurons, which is considered responsible for the fluctuations of clinical response. In this respect, apomorphine administration, via infusion pump, may be a good therapeutic option, aimed at obtaining continuous receptor stimulation, assisting in the management of motor fluctuations in the advanced phase of the disease. SN - 1590-1874 UR - https://www.unboundmedicine.com/medline/citation/19381769/Use_of_apomorphine_in_Parkinson's_disease_ L2 - https://link.springer.com/10.1007/s10072-008-1053-8 DB - PRIME DP - Unbound Medicine ER -